Woodline Partners LP Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Woodline Partners LP acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 450,199 shares of the biotechnology company's stock, valued at approximately $3,385,000. Woodline Partners LP owned about 0.22% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of BCRX. Venturi Wealth Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at about $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $48,000. KBC Group NV lifted its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $80,000. Finally, Syon Capital LLC bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $99,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BCRX. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price for the company. JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock traded up $0.31 during trading hours on Thursday, hitting $10.87. The company had a trading volume of 2,400,378 shares, compared to its average volume of 3,027,901. The firm has a market cap of $2.27 billion, a P/E ratio of -17.86 and a beta of 1.08. The company has a 50-day moving average price of $8.55 and a two-hundred day moving average price of $8.11. BioCryst Pharmaceuticals, Inc. has a 1 year low of $5.92 and a 1 year high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analysts' expectations of $126.64 million. The business's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.